Press release
Hemophilia A Treatment Market to Witness Growth Acceleration During 2018-2022 | Industry Players : BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd and Others
Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-sample?utm_source=openpr.com&utm_medium=referral&utm_campaign=KDM_15april_Hemophilia_a_Treatment_sample&utm_content=content
According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.
As of January 2018, there are over 450 reported Clinical Trials for Hemophilia A with 50+ trials currently actively ongoing. Out of all the trials, 120+ studies are funded by the pharmaceutical companies alone. The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.
Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment. The United States dominates the Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis segments are predicted to be the fastest growing segment whereas the on-demand therapy segment is expected to contribute close to ~50% to the market during the forecast period. With the increase in the R&D investments and rising drug innovations in this field, the market is expected to significantly expand in the next five years.
Browse for full research summary: https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market?utm_source=openpr.com&utm_medium=referral&utm_campaign=KDM_15april_Hemophilia_a_Treatment&utm_content=content
RNA based therapeutics and curative gene therapies are rapidly progressing through clinical development and are seen as an attractive segment of this market.
Polaris Market Research has provided the forecasts of the Global Hemophilia A Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:
• Market Analysis by Hemophilia A treatment
• Market Analysis by Treatments/Marketed Drugs
• Market Analysis by G7 countries
The Marketed Therapies undertaken in forecast from 2016-2022 are:
• Afstyla Sales Forecast-2016-2022
• Eloctate Sales Forecast-2016-2022
• Hemlibra Sales Forecast-2016-2022
• Kogenate FS Sales Forecast-2016-2022
• Kovaltry Sales Forecast-2016-2022
• Nuwiq Sales Forecast-2016-2022
• Obizur Sales Forecast-2016-2022
The Major Indications in Hemophilia A Therapy area:
• Prophylaxis-Market Forecast 2016-2022
• On-demand therapy-Market Forecast 2016-2022
• Inhibitor therapy- Market Forecast 2016-2022
The Market Forecast of Hemophilia A Treatment by G7 Countries (2016-2022)
• United States- Market Forecast (2016-2022)
• Germany- Market Forecast (2016-2022)
• France-Market Forecast (2016-2022)
• Italy- Market Forecast (2016-2022)
• Spain- Market Forecast (2016-2022)
• United Kingdom- Market Forecast (2016-2022)
• Japan- Market Forecast (2016-2022)
Check for discount: https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-discount-pricing?utm_source=openpr.com&utm_medium=referral&utm_campaign=KDM_15april_Hemophilia_a_Treatment_discount&utm_content=content
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities.
Contact us-
Mr. Rohit
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia A Treatment Market to Witness Growth Acceleration During 2018-2022 | Industry Players : BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd and Others here
News-ID: 1703134 • Views: …
More Releases from Polaris Market Research & Consulting
U.S. Riflescopes & Red Dot Sight Market Outlook to 2034: Key Trends, Investment …
Polaris Market Research recently introduced the latest update on U.S. Riflescopes & Red Dot Sight Market that provides an extensive outlook of the market, analyzing key growth opportunities, challenges, risk factors, and emerging trends across diverse geographic regions. The report offers a definitive and meticulous analysis of the U.S. Riflescopes & Red Dot Sight market size, share, demand, key growth factors, segmentation, country-level overview, and forecast.
The report helps businesses get…
U.S. Blank Apparel Market on Track for USD 5.92 Billion By 2034, Growing at a 5. …
Polaris Market Research recently introduced the latest update on U.S. Blank Apparel Market that provides an extensive outlook of the market, analyzing key growth opportunities, challenges, risk factors, and emerging trends across diverse geographic regions. The report offers a definitive and meticulous analysis of the U.S. Blank Apparel market size, share, demand, key growth factors, segmentation, country-level overview, and forecast.
The report helps businesses get a thorough understanding of the industry…
U.S. Small Molecule CDMO Market Forecast 2025-2034: Key Trends, Growth Opportuni …
Polaris Market Research recently introduced the latest update on U.S. Small Molecule CDMO Market that provides an extensive outlook of the market, analyzing key growth opportunities, challenges, risk factors, and emerging trends across diverse geographic regions. The report offers a definitive and meticulous analysis of the U.S. Small Molecule CDMO market size, share, demand, key growth factors, segmentation, country-level overview, and forecast.
The report helps businesses get a thorough understanding of…
U.S. Liquid Embolic Agent Market Forecast to Hit USD 156.91 Million by 2034 with …
Polaris Market Research recently introduced the latest update on U.S. Liquid Embolic Agent Market that provides an extensive outlook of the market, analyzing key growth opportunities, challenges, risk factors, and emerging trends across diverse geographic regions. The report offers a definitive and meticulous analysis of the U.S. Liquid Embolic Agent market size, share, demand, key growth factors, segmentation, country-level overview, and forecast.
The report helps businesses get a thorough understanding of…
More Releases for Hemophilia
Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Is the Expected CAGR for the Hemophilia Market Through 2025?
In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)…
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028.
During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis.
Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and…
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748
This latest report researches the industry structure,…
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand…
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports.
Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged…
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes…
